Santen acquires Eyevance
Santen has acquired Eyevance through a share purchase agreement, according to a press release.
The $225 million all-cash transaction makes Eyevance a wholly owned subsidiary of Santen.
Current Eyevance offerings include anti-inflammatory, anti-allergic, antifungal, anti-infective/anti-inflammatory fixed combination and tear lubricant products. Two products under development, Visovanq, a sterile vancomycin ophthalmic ointment, and Nexagon, a gel for persistent corneal epithelial defects, were excluded from the deal.
“Through this purchase, we will quickly establish a business base in the U.S. and both humbly face and further contribute to the needs of a greater number of patients by offering more value,” Shigeo Taniuchi, Santen president and CEO, said in the release. “At the same time, we will accelerate global business rollout by gaining access to the U.S. and our presence in the market, aiming for even further corporate growth and contribution to ophthalmic treatments for people around the world.”